# Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

> **NCT04978688** · PHASE1 · COMPLETED · sponsor: **Myovant Sciences GmbH** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Relugolix
- **DRUG:** E2/NETA

## Key facts

- **NCT ID:** NCT04978688
- **Lead sponsor:** Myovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-16
- **Primary completion:** 2016-09-21
- **Final completion:** 2016-09-21
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978688, "Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04978688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*